TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy

Zacks12-06

Shares of Protara Therapeutics TARA rallied 70% on Wednesday after the company announced compelling results from the pre-planned interim analysis of its ongoing mid-stage study evaluating intravesical...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489615258?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rP1EV4y5.bnG6Q.bCrRgNA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/22d93c77b91a36ccc2d6a44613af467e","is_english":true,"pubTime":"2024-12-06 22:34","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2489615258","market":"us","top_or_hot":-1,"title":"TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy","media":"Zacks","content":"<div>\n<p>Shares of Protara Therapeutics TARA rallied 70% on Wednesday after the company announced compelling results from the pre-planned interim analysis of its ongoing mid-stage study evaluating intravesical...</p>\n\n<a href=\"https://finance.yahoo.com/news/tara-stock-soars-superior-efficacy-143400446.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTARA Stock Soars on Superior Efficacy of Bladder Cancer Cell Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-06 22:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/tara-stock-soars-superior-efficacy-143400446.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Protara Therapeutics TARA rallied 70% on Wednesday after the company announced compelling results from the pre-planned interim analysis of its ongoing mid-stage study evaluating intravesical...</p>\n\n<a href=\"https://finance.yahoo.com/news/tara-stock-soars-superior-efficacy-143400446.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://finance.yahoo.com/news/tara-stock-soars-superior-efficacy-143400446.html","article_id":"2489615258","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rP1EV4y5.bnG6Q.bCrRgNA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/22d93c77b91a36ccc2d6a44613af467e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489615258","pubTimestamp":1733495640,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Shares of Protara Therapeutics TARA rallied 70% on Wednesday after the company announced compelling results from the pre-planned interim analysis of its ongoing mid-stage study evaluating intravesical TARA-002 for treating non-muscle invasive bladder cancer .TARA-002 is Protara’s investigational cell therapy, which is currently in development for treating NMIBC and lymphatic malformations . The candidate enjoys the FDA’s Rare Pediatric Disease designation for treating these indications in the United States.NMIBC patients treated with TARA-002 achieved a complete response  rate of 72% at six months and 70% at any time across BCG exposures with 100% of patients maintaining a CR from three months to six months. Protara also reported that two out of three treated patients maintained a CR at nine months.In the past three months, shares of TARA have skyrocketed 227.2% against the industry’s 7.3% decline.Apart from TARA-002, Protara’s clinical pipeline comprises an investigational IV phosphol","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","CR":"crane","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","PFE":"辉瑞","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","TARA":"ArTara Therapeutics, Inc.","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4532":"文艺复兴科技持仓","BK4599":"减肥药","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4161":"工业机械","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","BCG":"Binah Capital Group Inc","BK4534":"瑞士信贷持仓","GILD":"吉利德科学","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","BK4585":"ETF&股票定投概念","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4139":"生物科技","BK4007":"制药","BK4566":"资本集团","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","ALNY":"阿尔尼拉姆制药公司","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0122379950.USD":"贝莱德世界健康科学A2","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999002232.USD":"Allianz Global High Payout USD","BK4588":"碎股","BK4550":"红杉资本持仓","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0058720904.USD":"联博国际健康护理基金A","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC"},"translate_title":"TARA股价因膀胱癌细胞疗法疗效卓越而飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCG":1,"TARA":1,"GILD":1,"CR":1,"ALNY":1,"PFE":0.9},"content_text":"Shares of Protara Therapeutics TARA rallied 70% on Wednesday after the company announced compelling results from the pre-planned interim analysis of its ongoing mid-stage study evaluating intravesical TARA-002 for treating non-muscle invasive bladder cancer (NMIBC).\nTARA-002 is Protara’s investigational cell therapy, which is currently in development for treating NMIBC and lymphatic malformations (LMs). The candidate enjoys the FDA’s Rare Pediatric Disease designation for treating these indications in the United States.\nPatients enrolled in the ongoing phase II ADVANCED-2 study were high-risk NMIBC patients with carcinoma in situ or CIS (± Ta/T1) who are Bacillus Calmette-Guérin (BCG)-Unresponsive or BCG-Naïve.\nNMIBC patients treated with TARA-002 achieved a complete response (CR) rate of 72% at six months and 70% at any time across BCG exposures with 100% of patients maintaining a CR from three months to six months. Protara also reported that two out of three treated patients maintained a CR at nine months.\nIn the past three months, shares of TARA have skyrocketed 227.2% against the industry’s 7.3% decline. \nImage Source: Zacks Investment Research\nMore Data From Protara’s Mid-Stage NMIBC Study\nIn the pivotal cohort of the ADVANCED-2 study focusing on BCG-unresponsive patients, the CR rate was 100% at six months and 80% at any time. In the proof-of-concept cohort involving BCG-naïve patients, the CR rate was 64% at six months and 67% at any time.\nTARA-002 exhibited a favorable safety and tolerability profile. All treatment-related adverse events reported were mild in severity and no patient discontinued treatment due to adverse events.\nBased on the encouraging clinical activity across BCG exposures, along with its ease of use and low procedural burden for physicians, Protara believes that TARA-002 has significant potential to become an important treatment option for NMIBC patients.\nBladder cancer ranks as the sixth most common cancer in the United States, with NMIBC accounting for about 80% of cases. Each year, approximately 65,000 individuals in the United States are diagnosed with NMIBC, a type of cancer confined to the bladder's inner lining that has not penetrated the muscle layer.\nTARA’s Clinical Pipeline Development Programs\nProtara continues to evaluate TARA-002 in the phase II ADVANCED-2 study for NMIBC and expects to report initial data from 12-month evaluable patients in mid-2025.\nThe company is also evaluating TARA-002 in an ongoing phase II STARBORN-1 study to treat pediatric patients with macrocystic and mixed cystic LMs. The study is currently enrolling patients with initial results expected in the first half of 2025.\nApart from TARA-002, Protara’s clinical pipeline comprises an investigational IV phospholipid substrate replacement therapy, IV Choline Chloride, which is being developed as a source of choline for adult and adolescent patients on parenteral support (PS). The company is currently gearing up to initiate dosing PS patients with IV Choline Chloride in its registrational phase IIb/III THRIVE-3 study in the first quarter of 2025. \nTARA’s IV Choline Chloride enjoys the FDA’s Fast Track designation in the United States for the PS indication.\n\nProtara Therapeutics, Inc. Price and Consensus\n\nProtara Therapeutics, Inc. price-consensus-chart | Protara Therapeutics, Inc. Quote\n\nTARA’s Zacks Rank & Stocks to Consider\nProtara currently carries a Zacks Rank #3 (Hold).\nSome better-ranked pharma stocks are Alnylam Pharmaceuticals ALNY, Pfizer PFE and Gilead Sciences GILD, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nOver the past 60 days, Alnylam Pharmaceuticals’ loss estimates have narrowed from 42 cents to 39 cents per share for 2024, while that for 2025 has narrowed from 49 cents to 13 cents. ALNY shares have lost 0.5% in the past three months.\nAlnylam Pharmaceuticals’ earnings beat estimates in three of the trailing four quarters and matched once, delivering an average surprise of 65.67%.\nIn the past 60 days, Pfizer’s earnings estimates have risen from $2.62 to $2.91 per share for 2024, while that for 2025 has increased from $2.84 to $2.91. PFE shares have lost 12.8% in the past three months.\nPfizer’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 74.50%.\nIn the past 60 days, Gilead Sciences’ earnings estimates have risen from $3.79 to $4.32 per share for 2024, while that for 2025 has increased from $7.24 to $7.38. GILD shares have risen 18% in the past three months.\nGilead Sciences’ earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 15.46%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAlnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report\nPfizer Inc. (PFE) : Free Stock Analysis Report\nGilead Sciences, Inc. (GILD) : Free Stock Analysis Report\nProtara Therapeutics, Inc. (TARA) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489615258"}